Comprehensive Assessment of the Stability of Selected Coxibs in Variable Environmental Conditions along with the Assessment of Their Potential Hepatotoxicity.
TLC-densitometry
UPLC-MS/MS
celecoxib
chemometry
cimicoxib
coxibs
degradation study
etoricoxib
firocoxib
hepatotoxicyty
robenacoxib
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
09 Nov 2023
09 Nov 2023
Historique:
received:
04
10
2023
revised:
06
11
2023
accepted:
07
11
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Determining the influence of environmental factors on the stability of drugs is very helpful when choosing excipients, storage conditions or packaging materials. In addition, information about possible toxic degradation products enables detecting and avoiding the harmful side effects of the drug. We used the thin-layer chromatographic-densitometric procedure for the assay of five coxibs, conducted degradation studies in various environments and at different temperatures along with the determination of pharmacokinetic parameters. The results were subjected to chemometric analysis, to investigate and visualize the similarities and differences of the studied coxibs. Samples of the tested drug were also analyzed by UPLC-MS/MS in order to identify degradation products, and determine possible drug degradation pathways. Using the human liver cancer HepG2 cell line, the hepatotoxic effect of the degradation products was also determined. It was observed that all substances were relatively stable under the analyzed conditions and degraded more in acidic than alkaline environments. Robenacoxib is the drug that decomposes the fastest, and cimicoxib turned out to be the most stable. Robenacoxib also showed significant hepatotoxicity at the highest tested concentration, which correlates with the high degree of its degradation, and the probable formation of a more hepatoxic product. The obtained mass spectra of compounds formed as a result of hydrolysis of the protonated drug leading to the formation of several product ions, which enabled us to propose probable degradation pathways.
Identifiants
pubmed: 38004587
pii: pharmaceutics15112609
doi: 10.3390/pharmaceutics15112609
pmc: PMC10674268
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Research Support Module as part of the Excellence Initiative-research university at the Jagiellonian University program
ID : U1C/W42/NO/28.06
Organisme : Jagiellonian University Medical College
ID : N42/DBS/000268
Références
Semin Arthritis Rheum. 2020 Apr;50(2):285-288
pubmed: 31439354
Toxicol In Vitro. 1997 Aug;11(4):385-92
pubmed: 20654325
J Biol Chem. 1990 Oct 5;265(28):16737-40
pubmed: 2120205
Basic Clin Pharmacol Toxicol. 2018 Jul;123(1):51-57
pubmed: 29377603
Int J Mol Sci. 2016 Feb 06;17(2):224
pubmed: 26861310
BMC Vet Res. 2013 Dec 11;9:250
pubmed: 24330630
Equine Vet J. 2014 Nov;46(6):734-8
pubmed: 24393414
Eur J Pharm Biopharm. 2016 Jan;98:26-46
pubmed: 26542454
Pharmaceuticals (Basel). 2010 Jul 07;3(7):2146-2162
pubmed: 27713346
Pharmacol Rev. 2004 Sep;56(3):387-437
pubmed: 15317910
Vet Med (Auckl). 2018 Aug 15;9:53-61
pubmed: 30148083
J Chromatogr B Biomed Sci Appl. 1999 Jul 9;730(2):221-7
pubmed: 10448957
Aust Vet J. 2020 Dec;98(12):578-585
pubmed: 32875570
J Chromatogr Sci. 2015 Jan;53(1):144-53
pubmed: 24837233
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jul 1;854(1-2):313-9
pubmed: 17537684
Pharmazie. 2004 Dec;59(12):913-9
pubmed: 15638077
Annu Rev Pharmacol. 1973;13:107-25
pubmed: 4576885
J Vet Pharmacol Ther. 2019 Sep;42(5):518-524
pubmed: 30888074
Prostaglandins Other Lipid Mediat. 2020 Apr;147:106379
pubmed: 31726219
J Vet Pharmacol Ther. 2009 Feb;32(1):41-8
pubmed: 19161454
Vet Med (Auckl). 2014 Nov 04;5:159-168
pubmed: 32670856
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31
pubmed: 12242329
Curr Med Res Opin. 2009 Aug;25(8):1841-51
pubmed: 19530981
BMJ. 2020 Jan 28;368:m311
pubmed: 31992540
J Vet Intern Med. 2005 Sep-Oct;19(5):633-43
pubmed: 16231707
Vet J. 2013 Nov;198(2):382-5
pubmed: 24076125
Fundam Clin Pharmacol. 2019 Apr;33(2):134-147
pubmed: 30383903
Drug Discov Today. 2016 Apr;21(4):598-615
pubmed: 26723915
J Int Med Res. 2016 Jun;44(3):483-95
pubmed: 26980340
J Pharm Biomed Anal. 2023 Feb 5;224:115192
pubmed: 36463770
J Pharm Biomed Anal. 2013 Sep;83:28-33
pubmed: 23685411
Reumatologia. 2017;55(6):290-297
pubmed: 29491537
J Gastroenterol Hepatol. 2012 Jun;27(6):1102-5
pubmed: 22142375
Toxicol Sci. 2002 Feb;65(2):166-76
pubmed: 11812920
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528
pubmed: 11087881
J Hazard Mater. 2018 Jan 15;342:252-259
pubmed: 28843794
Clin Rheumatol. 2016 Jan;35(1):151-8
pubmed: 26099603
Vet J. 2014 Apr;200(1):77-81
pubmed: 24461644